vorinostat has been researched along with Ewing Sarcoma in 6 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Compared with FDA-approved PARP (olaparib) and HDAC (vorinostat) inhibitors, kt-3283 displayed enhanced cytotoxicity in Ewing sarcoma models." | 4.31 | A Bifunctional PARP-HDAC Inhibitor with Activity in Ewing Sarcoma. ( Adomat, H; Bacha, J; Brown, D; Collins, C; Daugaard, M; Ghaidi, F; Joshi, J; Kung, SHY; Lallous, N; Langlands, J; Le Bihan, S; Lizardo, MM; Oo, HZ; Ramos, L; Rezakhanlou, AM; Shen, W; Shyp, T; Sorensen, PH; Truong, S; Zhai, B, 2023) |
| "Several cancers, however, fail to respond to TRAIL's antineoplastic effects." | 1.38 | Histone deacetylase inhibitor-mediated sensitization to TRAIL-induced apoptosis in childhood malignancies is not associated with upregulation of TRAIL receptor expression, but with potentiated caspase-8 activation. ( Beck, JF; Becker, S; Grauel, D; Palani, CD; Sonnemann, J; Trommer, N; Wittig, S, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Ramos, L | 1 |
| Truong, S | 1 |
| Zhai, B | 1 |
| Joshi, J | 1 |
| Ghaidi, F | 1 |
| Lizardo, MM | 1 |
| Shyp, T | 1 |
| Kung, SHY | 1 |
| Rezakhanlou, AM | 1 |
| Oo, HZ | 1 |
| Adomat, H | 1 |
| Le Bihan, S | 1 |
| Collins, C | 1 |
| Bacha, J | 1 |
| Brown, D | 1 |
| Langlands, J | 1 |
| Shen, W | 1 |
| Lallous, N | 1 |
| Sorensen, PH | 1 |
| Daugaard, M | 1 |
| Unland, R | 1 |
| Clemens, D | 1 |
| Heinicke, U | 1 |
| Potratz, JC | 1 |
| Hotfilder, M | 1 |
| Fulda, S | 1 |
| Wardelmann, E | 1 |
| Frühwald, MC | 1 |
| Dirksen, U | 1 |
| Sampson, VB | 1 |
| Vetter, NS | 1 |
| Kamara, DF | 1 |
| Collier, AB | 1 |
| Gresh, RC | 1 |
| Kolb, EA | 1 |
| Pattenden, SG | 1 |
| Simon, JM | 1 |
| Wali, A | 1 |
| Jayakody, CN | 1 |
| Troutman, J | 1 |
| McFadden, AW | 1 |
| Wooten, J | 1 |
| Wood, CC | 1 |
| Frye, SV | 1 |
| Janzen, WP | 1 |
| Davis, IJ | 1 |
| Sonnemann, J | 2 |
| Trommer, N | 1 |
| Becker, S | 1 |
| Wittig, S | 1 |
| Grauel, D | 1 |
| Palani, CD | 2 |
| Beck, JF | 2 |
| Dreyer, L | 1 |
| Hartwig, M | 1 |
| Hong, le TT | 1 |
| Klier, U | 1 |
| Bröker, B | 1 |
| Völker, U | 1 |
6 other studies available for vorinostat and Ewing Sarcoma
| Article | Year |
|---|---|
A Bifunctional PARP-HDAC Inhibitor with Activity in Ewing Sarcoma.
Topics: Animals; Histone Deacetylase Inhibitors; Humans; Poly(ADP-ribose) Polymerase Inhibitors; Puma; Sarco | 2023 |
Suberoylanilide hydroxamic acid synergistically enhances the antitumor activity of etoposide in Ewing sarcoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Bone Neoplasms; Cell Proliferation; Drug Synergism; Etoposide; His | 2015 |
Vorinostat Enhances Cytotoxicity of SN-38 and Temozolomide in Ewing Sarcoma Cells and Activates STAT3/AKT/MAPK Pathways.
Topics: Acetylation; Antineoplastic Agents; Apoptosis; Camptothecin; Caspase 3; Cell Line, Tumor; Cell Proli | 2015 |
High-throughput small molecule screen identifies inhibitors of aberrant chromatin accessibility.
Topics: Antineoplastic Agents; Bone Neoplasms; Cell Line, Tumor; Chromatin; Drug Design; Drug Evaluation, Pr | 2016 |
Histone deacetylase inhibitor-mediated sensitization to TRAIL-induced apoptosis in childhood malignancies is not associated with upregulation of TRAIL receptor expression, but with potentiated caspase-8 activation.
Topics: Apoptosis; Bone Neoplasms; Caspase 8; Cell Line, Tumor; Enzyme Activation; Histone Deacetylase Inhib | 2012 |
Histone deacetylase inhibitors induce cell death and enhance the apoptosis-inducing activity of TRAIL in Ewing's sarcoma cells.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Butyrates; Caspase 3; Caspase 9; Caspases; Cell Line, | 2007 |